CEO Paul Wagner highlighted the progress of FB102, stating that the topline results from the phase 2 celiac disease study are expected in 2026, following positive results from the phase 1b trial reported in June 2025. The company also anticipates topline results from the phase 1b vitiligo study in the first half of 2026. With a cash balance of $77 million at the end of Q4 2025, Forte is well-positioned to continue its clinical development efforts.
Despite the increased expenses, the company reported a net loss per share of $(4.71) for 2025, an improvement from $(12.17) in 2024. The decrease in losses reflects the company's ongoing efforts to manage costs while advancing its clinical programs. Forte's strategic focus on addressing significant unmet medical needs across multiple indications presents substantial market opportunities, potentially validating FB102's therapeutic potential.
The filing also included a press release as Exhibit 99.1, detailing these financial results and updates on clinical trials. Investors and stakeholders are encouraged to review the full report for a comprehensive understanding of the company's financial health and strategic direction moving forward.
